A single-dose, randomized crossover study in healthy Chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0284576 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Yanmei Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, China. Hauptthemen laut MEDLINE: Calcium Dobesilate, East Asian People, Feeding Behavior, Drugs, Generic. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Science and Technology Commission.
Abstract (Originalsprache)
Objectives
To compare the rate and extent of absorption of a launched generic calcium dobesilate capsule versus the branded reference formulation under fasting and fed conditions in healthy Chinese subjects, and to assess their bioequivalence and tolerability.
Methods
This single-dose, open-label, randomized-sequence, 2-period crossover bioequivalence study was conducted on healthy Chinese volunteers aged 18 to 45 years. Subjects received a single 0.5 g dose of calcium dobesilate capsule under fasting or fed conditions, with a 3-day washout period between doses of the test (T) and reference (R) formulations. Blood samples were collected before and up to 24 hours after administration. The plasma concentration of calcium dobesilate was determined by a validated Liquid chromatography-tandem mass spectrometry method. Non-compartmental analysis was applied to identify the pharmacokinetic (PK) properties. The primary PK parameters including the maximal plasma concentration (C max ), the area under the plasma concentration-time curve (AUC 0-t ), and the AUC extrapolated to infinity (AUC 0-inf ) were used for bioequivalence evaluation.
Results
The mean of PK parameters for T and R capsules under fasting (fed) condition were: C max , 13.57 (6.71) and 12.59 (7.25) μg/mL; AUC 0-t , 97.32 (79.74) and 96.97 (80.71) h*μg/mL; AUC 0-inf , 101.68 (88.01) and 101.64 (87.81) h*μg/mL. The 90% confidence intervals (CIs) of GMRs under fasting (fed) condition were: C max , 97.91%-116.62% (88.63%-96.53%); AUC 0-t , 97.15%-104.00% (96.58%-101.39%); and AUC 0-inf , 97.19%-102.89% (98.67%-103.99%). These 90% CIs were all within the bioequivalence range of 80%-125%. All adverse events were mild.
Conclusion
In this study, the T calcium dobesilate 0.5 g capsule was bioequivalent to the reference product under both fasting and fed conditions. Taking food would slow down its rate and reduce its amount of absorption. Both formulations were generally well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, China.
- Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.
- Shanghai Zhaohui Pharmaceutical Co., Ltd., Shanghai, China.
- Shanghai Center of Biomedicine Development, Shanghai, China.
ORCID-Profile: Jingying Jia
Förderung
- Shanghai Municipal Science and Technology Commission
Zitieren
APA
Liu, Y., Cheng, J., Liang, L., Qian, W., Ou, M., Zhang, M., Wang, Y., Wang, Y., Peng, K., & Jia, J. (2023). A single-dose, randomized crossover study in healthy Chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions. PLOS ONE. https://doi.org/10.1371/journal.pone.0284576
Vancouver
Liu Y, Cheng J, Liang L, Qian W, Ou M, Zhang M, et al. A single-dose, randomized crossover study in healthy Chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions. PLOS ONE. 2023. doi:10.1371/journal.pone.0284576
BibTeX
@article{Liu2023,
author = {Liu, Yanmei and Cheng, Jie and Liang, Liyu and Qian, Weigang and Ou, Meixian and Zhang, Mengqi and Wang, Yijun and Wang, Yan and Peng, Ka and Jia, Jingying},
title = {A single-dose, randomized crossover study in healthy Chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0284576}
}
EUVIMED